ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
To demonstrate that losartan (+ conventional therapy) compared to placebo (+ conventional
therapy) will reduce the number of RT patients who experience histological lesions of chronic
allograft nephropathy